IgniteData has completed the final close of its oversubscribed Series A funding round, bringing the total capital raised to $11 million. The investment will support the company’s continued global expansion, product development, and innovation in the automation of clinical trial data using generative AI.
Based in New Castle, IgniteData develops technology that automates the movement of clinical trial data between healthcare providers and life science organizations. Its flagship platform, Archer, is designed to transfer data directly from electronic health records into electronic data capture systems and data warehouses. By automating these workflows, the company aims to reduce the operational burden on research sites, accelerate clinical trial timelines, and improve data quality.
FCA Venture Partners led the funding round. The Labcorp Venture Fund and Epsilon anchored the final close, joining a strong group of returning and new investors, including SpringTide and Oncology Ventures. Several industry leaders also participated personally, including Thomas Tarnowski, Marc Vangerven, and Andy Cooper, CEO of CluePoints. Their involvement is positioned as both strategic and operationally significant as IgniteData scales.
The company plans to expand its network of research sites and increase investment in large language model capabilities and intelligent data mapping technologies. These advancements aim to unlock access to previously inaccessible clinical data and enhance collaboration between trial sponsors and research centers.
Existing investors increased their positions in the round, signaling confidence in the company’s progress and market opportunity. IgniteData currently partners with life science companies and research institutions globally, with deployments in premier research environments and active integration of generative AI into study workflows.
KEY QUOTES
“This round is about scale. The demand for smarter, faster clinical trials is exploding. With Labcorp and Epsilon joining as primary investors in our Series A, and with the addition of Thomas, Marc, and Andy to our team, we gain not just capital but also invaluable expertise and endorsement from leaders who have shaped this industry. Their confidence underscores the transformative potential of our platform — particularly as we continue to harness generative AI and intelligent data mapping to fundamentally change how clinical data flows between sites and sponsors.”
Zach Taft, CEO of IgniteData
“At Labcorp, we see tremendous value in innovations that reduce site burden and enable more efficient, higher-quality clinical trials. We’re thrilled to support IgniteData on their journey to transform the way hospitals, research sites and sponsors transfer patient data for clinical research and trials.”
Megann Vaughn Watters, Vice President of New Ventures and Strategic Alliances, Labcorp
“Epsilon is committed to advancing healthcare through cutting-edge technology and data-driven solutions. IgniteData’s approach to intelligent data automation is transformative for clinical trials, and we are excited to support their continued growth and global expansion.”
Gregory Epstein, Managing Partner, Epsilon
“We backed IgniteData early because we believed in their vision to revolutionize clinical trials through intelligent automation. Today, we’re doubling down because they’ve exceeded expectations.”
Ryan Morley, Partner, SpringTide
